Evidence map›Paper›PMID 39803435›Full record

ArticlebioRxiv : the preprint server for biology2024

A generative framework for enhanced cell-type specificity in rationally designed mRNAs.

Matvei Khoroshkin, Arsenii Zinkevich, Elizaveta Aristova, Hassan Yousefi, Sean B Lee, Tabea Mittmann, Karoline Manegold, Dmitry Penzar, David R Raleigh, Ivan V Kulakovskiy and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matvei KhoroshkinDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Arsenii ZinkevichFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Elizaveta AristovaFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Hassan YousefiDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Sean B LeeDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Tabea MittmannDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Karoline ManegoldDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Dmitry PenzarInstitute of Protein Research, Russian Academy of Sciences, Pushchino, Russia.
David R RaleighHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Ivan V KulakovskiyInstitute of Protein Research, Russian Academy of Sciences, Pushchino, Russia.
Hani GoodarziDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9648-8949

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EMILY K BERGSLAND · 1999 to 2026
$209.7M
Mechanisms of Hedgehog signaling in glioblastomaR01CA251221 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2021 to 2025
$2.6M
NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA251221
6 · The paper itself

Abstract

mRNA delivery offers new opportunities for disease treatment by directing cells to produce therapeutic proteins. However, designing highly stable mRNAs with programmable cell type-specificity remains a challenge. To address this, we measured the regulatory activity of 60,000 5' and 3' untranslated regions (UTRs) across six cell types and developed PARADE (Prediction And RAtional DEsign of mRNA UTRs), a generative AI framework to engineer untranslated RNA regions with tailored cell type-specific activity. We validated PARADE by testing 15,800 de novo-designed sequences across these cell lines and identified many sequences that demonstrated superior specificity and activity compared to existing RNA therapeutics. mRNAs with PARADE-engineered UTRs also exhibited robust tissue-specific activity in animal models, achieving selective expression in the liver and spleen. We also leveraged PARADE to enhance mRNA stability, significantly increasing protein output and therapeutic durability in vivo. These advancements translated to notable increases in therapeutic efficacy, as PARADE-designed UTRs in oncosuppressor mRNAs, namely PTEN and P16, effectively reduced tumor growth in patient-derived neuroglioma xenograft models and orthotopic mouse models. Collectively, these findings establish PARADE as a versatile platform for designing safer, more precise, and highly stable mRNA therapies.

Identifiers

PMID39803435
PMCPMC11722239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.